Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Purchased by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB boosted its position in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 33.3% in the third quarter, HoldingsChannel.com reports. The fund owned 180,100 shares of the company’s stock after acquiring an additional 45,000 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Structure Therapeutics were worth $5,043,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. DNB Asset Management AS lifted its holdings in shares of Structure Therapeutics by 21.2% during the third quarter. DNB Asset Management AS now owns 12,888 shares of the company’s stock worth $361,000 after purchasing an additional 2,253 shares during the period. Private Capital Advisors Inc. purchased a new stake in Structure Therapeutics in the third quarter valued at approximately $1,545,000. EverSource Wealth Advisors LLC increased its holdings in Structure Therapeutics by 530.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after buying an additional 901 shares during the period. ANTIPODES PARTNERS Ltd raised its position in Structure Therapeutics by 39.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock worth $114,000 after buying an additional 1,146 shares during the last quarter. Finally, Readystate Asset Management LP raised its position in Structure Therapeutics by 32.8% during the 3rd quarter. Readystate Asset Management LP now owns 237,188 shares of the company’s stock worth $6,641,000 after buying an additional 58,576 shares during the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Citizens Jmp dropped their price objective on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a report on Friday, February 27th. Morgan Stanley raised their target price on shares of Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. HC Wainwright boosted their target price on shares of Structure Therapeutics from $90.00 to $114.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. The Goldman Sachs Group raised shares of Structure Therapeutics to a “strong-buy” rating in a report on Tuesday, January 20th. Finally, Wall Street Zen upgraded Structure Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $107.90.

Key Stories Impacting Structure Therapeutics

Here are the key news stories impacting Structure Therapeutics this week:

• Positive Sentiment: HC Wainwright retained a “Buy” rating and a $114 price target on GPCR, signaling continued analyst conviction in the company’s longer‑term clinical/strategic potential. Price Target Raised to $114.00
• Neutral Sentiment: Consensus current‑year EPS remains negative at about ($0.82) per share — consistent with a development‑stage biotech profile where revenue is limited and earnings are driven by R&D/SG&A spend. GPCR MarketBeat page
• Negative Sentiment: HC Wainwright sharply cut near‑term and multi‑year EPS forecasts across the board — Q1–Q4 2026 and FY2026–FY2030 were all revised lower (examples: FY2026 from about ($1.20) to ($1.72); FY2027 from ($1.70) to ($2.34)). Those downgrades imply higher expected cash burn or later commercialization/timeline risk and are likely the primary driver of today’s negative price action. HC Wainwright estimates (MarketBeat)

Structure Therapeutics Trading Down 3.3%

Shares of GPCR opened at $57.73 on Friday. The firm has a market cap of $4.08 billion, a P/E ratio of -73.08 and a beta of -1.80. Structure Therapeutics Inc. Sponsored ADR has a 12 month low of $13.22 and a 12 month high of $94.90. The stock’s 50 day moving average is $74.68 and its two-hundred day moving average is $48.20.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14). Equities research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.